Hoe werkt ENHERTU®?

Belangrijkste kenmerken

Lijst van afkortingen:

ADC: Antilichaam-geneesmiddelconjugaat

HER2: Receptor 2 van de menselijke epidermale groeifactor

 

Referenties :

1 Yver A, et al. The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers . Ann Oncol 2020;31:430–34. 2 ENHERTU® (trastuzumab déruxtécan). Résumé des caractéristiques du produit. Dernière version. 3 Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T- DM1 Clin Cancer Res. 2016;22(20):5097–5108 4 Nakada T, et al. The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy Chem Pharm Bull (Tokyo). 2019;67(3):173-185.